Our Science
An evidence-based artisan method engineered to address the metabolic, inflammatory, and microbiome challenges of modern wheat — without compromising on taste, craft, or commercial viability.
The Clinical Context
Metabolic disease has become the dominant chronic health burden in the United States. Behind the numbers lies a structural food-system problem: modern refined wheat products, engineered for industrial scale and shelf life, drive glycemic volatility, inflammatory load, and gut dysfunction in a population already under metabolic stress.
Americans with diabetes (1 in 8 adults)
CDC National Diabetes Statistics Report, 2026US adults with prediabetes (more than 2 in 5)
8 in 10 are unaware of their conditionof US healthcare spending tied to diabetes
Direct medical costs 2.6× higher in diabeticsNearly 1 in 3 US adolescents (12–17) now present with prediabetes — a generational signal that current food defaults are failing.
Sources — CDC · NHANES · American Diabetes AssociationThe Wheat–Inflammation–Gut Axis
Hexaploid Triticum aestivum — selected for industrial yield, gluten strength, and shelf life rather than digestibility — drives a converging cluster of clinical issues. The mechanisms are now well characterized in the peer-reviewed literature.
| Mechanism | Biochemical Process | Clinical Correlate |
|---|---|---|
| Amylase-trypsin inhibitors (ATIs) | Activation of TLR4 on innate immune cells, driving low-grade systemic inflammation independent of gluten itself. | NCWS · extra-intestinal inflammation |
| Hexaploid gliadin profile | Higher density of immunogenic gluten peptides resistant to gastric and pancreatic proteolysis. | NCGS · GI symptoms · brain fog |
| FODMAPs (fructans) | Rapid colonic fermentation, gas distension, osmotic load. | IBS · bloating · post-meal fatigue |
| High glycemic index | Rapid α-amylase action on refined starch — sharp postprandial glucose & insulin spike. | T2D progression · weight gain · cravings |
| Phytate–mineral complexation | Native phytic acid binds Fe, Zn, Mg, Ca; bioavailability compromised in unfermented wheat. | Subclinical micronutrient deficiency |
The Blueprint Mechanism
Diploid, 14-chromosome, never hybridized in 10,000 years. Distinct gliadin epitope profile vs. modern T. aestivum. Lower ATI content. Higher native carotenoid, lutein, and mineral density. The most pristine wheat species commercially available.
Lactic acid and acetic acid bacteria consortium. Endogenous proteolysis of gliadin peptides. Phytase activation — mineral release. Organic acid production lowers postprandial glycemic response independent of starch composition.
Long-duration enzymatic hydrolysis. Starch retrogradation increases the resistant-starch fraction. Continued FODMAP degradation. Sensory and digestive optimization documented in controlled studies. Specific timing parameters remain proprietary.
Documented Downstream Effects
On einkorn and long-fermentation sourdough systems.
Applications
The methodology was first developed and validated in the pizza format — chosen as a proof-of-concept because it is one of the most consumed wheat-based foods globally and the hardest to reformulate without sensory loss. The same fermented einkorn base, with adjusted hydration and process parameters, transfers directly to other wheat-based formats.
Boules, baguettes, sandwich loaves. Direct transfer of the methodology with retail-grade shelf life and ambient stability.
Hamburger buns, brioche buns, slider rolls, hot-dog buns — for QSR chains and industrial foodservice operators seeking digestibility differentiation.
Ferment-matrix biscuit format — small, ambient-stable, postbiotic-active. Particularly relevant for the GLP-1 inter-meal gap and specialized nutrition channels.
Fresh-extruded and dried pasta, ravioli, gnocchi, focaccia, pizza dough balls — wherever fermented dough quality and digestibility matter.
Each format requires specific adaptation of hydration, fermentation timing, and process parameters. The core biochemistry — einkorn + wild sourdough consortium + extended cold maturation — remains constant. Industrial scaling is supported through licensing partnerships and certified production sites.
Glycemic Profile
Wheat-based foods — bread, pizza, buns, pasta — are daily caloric vehicles for hundreds of millions of consumers. Reformulating the base flour and fermentation profile alone produces a clinically meaningful glycemic shift, with no behavioral change required of the end consumer. The values below illustrate the effect on a pizza dough format; the same biochemistry applies across formats with format-specific calibration.
| Dough Formulation | Glycemic Index | Metabolic Profile |
|---|---|---|
| Conventional refined white flour, commercial yeast, short proof |
85–90 | Sharp postprandial glucose spike |
| Artisan T80 flour, yeast, short fermentation |
~65 | Elevated GI · limited tolerance |
| ORA 1929 Blueprint einkorn flour, wild sourdough, extended cold ferment |
~35–40 | Low-GI · compatible with glycemic management protocols |
GI reduction is driven by three compounding mechanisms: (i) the lower inherent starch-to-fiber ratio of einkorn, (ii) organic-acid generation during LAB fermentation, and (iii) starch retrogradation across extended cold maturation. Estimated values based on published einkorn flour data and peer-reviewed sourdough literature. Independent clinical validation of the finished ORA 1929 product is currently in scoping with an independent research laboratory.
References — INRAE · Syracuse University, mSystems · International Table of GI Values (Atkinson, Foster-Powell, Brand-Miller, 2021)Proof of Concept
Las Vegas — March 2026
Traditional American category, 730+ international competitors. Ranked under blind-tasting conditions using a low-GI einkorn sourdough against a field dominated by conventional high-GI formulations. The result demonstrates that fermented einkorn does not concede sensory ground to refined-flour systems — it competes and wins on equal footing.
Paris — April 2026
Parizza + Gusto Exhibition. National-level sensory validation of the platform’s gastronomic parity with conventional dough, on a signature technical plate built on einkorn sourdough. A second independent jury, a second confirmation.
“Ancestral grain and wild fermentation are not a sensory compromise. Under identical judging conditions, they are a measurable competitive advantage.”— Boris Berard, Founder · ORA 1929
Intellectual Property & Licensing
The ORA 1929 Blueprint is IP-protected. A French INPI envelope has been filed in 2025 covering the methodology, and a USPTO patent process is underway in parallel for the U.S. market.
The complete protocol — including specific fermentation parameters, LAB/AAB strain selection, hydration ratios, temperature profiles, and standardization controls — is shared exclusively with licensing partners under NDA.
Public-facing scientific descriptions on this page do not disclose the proprietary parameters required for industrial reproducibility. The methodology is structured for deployment at certified production sites with full traceability and quality control.
Clinical Protocols Available for Co-Design
For physicians, researchers, and clinical teams interested in formal investigation, three standardized protocols are available for academic or clinical partner co-investigation. Product is fully standardized, reproducible, and traceable — meeting research-grade dietary intervention requirements.
Randomized crossover. Continuous glucose monitoring (CGM) in healthy and prediabetic adults. Blueprint vs. matched conventional pizza — isocaloric, identical macronutrient profile.
Endpoints: 2h glucose AUC · peak excursion · time-in-range. n ≈ 30.
4-week dietary substitution (3 Blueprint meals/week vs. control). Stool 16S rRNA + metabolomics. Pre / mid / post sampling.
Endpoints: SCFA profile · genus-level shifts · alpha & beta diversity. n ≈ 40.
Single-blind tolerability trial in self-reported NCGS or IBS-D subjects. Symptom diary + IBS-SSS + serum zonulin.
Endpoints: symptom severity delta · biomarker shift. 6 weeks. n ≈ 25.
Engage With Our Science
We welcome scientific advisory engagement, clinical pilot co-investigation, and editorial partnerships from professionals working at the intersection of nutrition, gastroenterology, and metabolic health.
